The new Levodopa pump has been approved by the FDA. Expected to be available through Medicare by summer 2025. Here is the link and followed by a Google Gemini created summary.
news.abbvie.com/2024-10-17-...
Summary & Explanation
The U.S. Food and Drug Administration (FDA) has approved VYALEV™ (foscarbidopa and foslevodopa) for adults with advanced Parkinson's disease. This is the first and only 24-hour continuous subcutaneous infusion levodopa-based therapy for treating motor fluctuations in this population.
Mechanism of Action: VYALEV™ delivers a continuous supply of levodopa, a crucial neurotransmitter for managing Parkinson's symptoms, throughout the day and night via subcutaneous infusion. This continuous delivery is designed to address the motor fluctuations experienced by patients with advanced Parkinson's disease, where oral medications become less effective.
Clinical Trial Results: Phase 3 clinical trials demonstrated that patients using VYALEV™ 0experienced a superior improvement in "on" time without troublesome dyskinesia compared to those using oral immediate-release carbidopa/levodopa. "On" time refers to periods when motor symptoms are well-controlled, while "off" time represents the return of symptoms. The improvement in "on" time was observed as early as the first week of treatment and persisted throughout the 12-week study period. A 52-week open-label study further evaluated the long-term safety and efficacy of VYALEV™.
Dosage and Administration: VYALEV™ offers personalized dosing to meet individual patient needs, adjusting for morning, daytime, and nighttime requirements. The medication is administered via continuous subcutaneous infusion.
Side Effects:The most common side effects were infusion site reactions, hallucinations, and dyskinesia (involuntary movements). Most reactions were non-serious and mild to moderate in severity. Serious side effects, including falling asleep unexpectedly during daily activities, hallucinations, unusual urges (such as gambling or compulsive shopping), and infusion site infections, were also reported and require immediate medical attention. Patients should inform their healthcare provider about all medications they are taking, as interactions with other drugs can occur.
Availability: The timing of patient access to VYALEV™ depends on individual insurance plans. Coverage for Medicare patients is anticipated in the second half of 2025.
LEVODOPA VERDICT: Start Early/Late = Same Outcomes
Long-lasting response to levodopa in Parkinson's. Another important discovery funded by the Grigioni FoundationTuesday, 07 July 2020.
Interesting Gender Research Findings RE: Levodopa Absorption Rates
Liquefy your L-dopa
Sinemet / carbidopa levodopa 
